Early liver metastases after "failure" of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?

被引:4
作者
Boerner, Thomas [1 ]
Zambirinis, Constantinos [1 ]
Gagniere, Johan [1 ,4 ,5 ]
Chou, Joanne F. [2 ]
Gonen, Mithat [2 ]
Kemeny, Nancy E. [3 ]
Cercek, Andrea [3 ]
Connell, Louise C. [3 ]
Kingham, Thomas P. [1 ]
Allen, Peter J. [1 ,6 ]
Balachandran, Vinod P. [1 ]
Drebin, Jeffrey [1 ]
Jarnagin, William R. [1 ]
D'Angelica, Michael, I [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA
[4] Clermont Auvergne Univ, Univ Hosp Clermont Ferrand, Dept Digest & Hepatobiliary Surg, Clermont Ferrand, France
[5] Clermont Auvergne Univ, U1071 Inserm, Clermont Ferrand, France
[6] Duke Univ, Dept Surg, Durham, NC USA
基金
美国国家卫生研究院;
关键词
HEPATIC ARTERIAL INFUSION; RANDOMIZED PHASE-III; COLON-CANCER; POOLED ANALYSIS; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; RESECTION; SURVIVAL; COMBINATION;
D O I
10.1016/j.hpb.2020.08.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The utility of adjuvant chemotherapy after resection of colorectal liver metastasis (CLM) in patients with rapid recurrence after adjuvant chemotherapy for their primary tumor is unclear. The aim of this study was to evaluate the oncologic benefit of adjuvant hepatic arterial plus systemic chemotherapy (HAIC + Sys) in patients with early CLM. Methods: A retrospective analysis of patients with early CLM ( 12 months of adjuvant chemotherapy for primary tumor) who received either HAIC + Sys, adjuvant systemic chemotherapy alone (Sys), or active surveillance (Surgery alone) following resection of CLM was performed. Recurrence and survival were compared between treatment groups using Kaplan?Meier methods and Cox proportional hazards models. Results: Of 239 patients undergoing resection of early CLM, 79 (33.1%) received HAIC + Sys, 77 (32.2%) received Sys, and 83 (34.7%) had Surgery alone. HAIC + Sys was independently associated with reduced risk of RFS events (adjusted hazard ratio [HRadj]: 0.64, 95%CI:0.44?0.94, p = 0.022) and allcause mortality (HRadj: 0.54, 95%CI:0.36?0.81, p = 0.003) compared to Surgery alone patients. Largest tumor 5 cm (HRadj: 2.03, 95%CI: 1.41?2.93, p < 0.001) and right-sided colon tumors (HRadj: 1.93, 95%CI: 1.29?2.89, p = 0.002) were independently associated with worse OS. Background: The utility of adjuvant chemotherapy after resection of colorectal liver metastasis (CLM) in patients with rapid recurrence after adjuvant chemotherapy for their primary tumor is unclear. The aim of this study was to evaluate the oncologic benefit of adjuvant hepatic arterial plus systemic chemotherapy (HAIC + Sys) in patients with early CLM. Methods: A retrospective analysis of patients with early CLM (<12 months of adjuvant chemotherapy for primary tumor) who received either HAIC + Sys, adjuvant systemic chemotherapy alone (Sys), or active surveillance (Surgery alone) following resection of CLM was performed. Recurrence and survival were compared between treatment groups using Kaplan-Meier methods and Cox proportional hazards models. Results: Of 239 patients undergoing resection of early CLM, 79 (33.1%) received HAIC + Sys, 77 (32.2%) received Sys, and 83 (34.7%) had Surgery alone. HAIC + Sys was independently associated with reduced risk of RFS events (adjusted hazard ratio [HRadj]: 0.64, 95%CI:0.44-0.94, p = 0.022) and all cause mortality (HRadj: 0.54, 95%CI:0.36-0.81, p = 0.003) compared to Surgery alone patients. Largest tumor >5 cm (HRadj: 2.03, 95%CI: 1.41-2.93, p < 0.001) and right-sided colon tumors (HRadj: 1.93, 95%CI: 1.29-2.89, p = 0.002) were independently associated with worse OS. Conclusion: Adjuvant HAIC + Sys after resection of early CLM that occur after chemotherapy for node positive primary is associated with improved outcomes.
引用
收藏
页码:601 / 608
页数:8
相关论文
共 50 条
  • [41] Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer
    Peixoto, Renata D'Alpino
    Kumar, Aalok
    Speers, Caroline
    Renouf, Daniel
    Kennecke, Hagen F.
    Lim, Howard J.
    Cheung, Winson Y.
    Melosky, Barbara
    Gill, Sharlene
    CLINICAL COLORECTAL CANCER, 2015, 14 (01) : 25 - 30
  • [42] Optimal adjuvant chemotherapy completion time for stage III colon cancer: a cohort study
    Ren, Jing-Qing
    Zhang, Han-Shuo
    Zhang, Li-Hua
    Zhong, Qi-Guang
    Wu, Fan
    Wang, Bai-Lin
    Liu, Shao-Jie
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (04) : 1558 - 1567
  • [43] Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer
    To, Yat Hang
    Degeling, Koen
    McCoy, Melanie
    Wong, Rachel
    Jones, Ian
    Dunn, Catherine
    Hong, Wei
    Loft, Matthew
    Gibbs, Peter
    Tie, Jeanne
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 (03) : 392 - 402
  • [44] Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer
    Tajima, Yosuke
    Shimada, Yoshifumi
    Kameyama, Hitoshi
    Yagi, Ryoma
    Okamura, Takuma
    Kobayashi, Takashi
    Kosugi, Shin-ichi
    Wakai, Toshifumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (04) : 313 - 320
  • [45] Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer
    Jeong, Woon Kyung
    Shin, Je-Wook
    Baek, Seong Kyu
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2015, 89 (03) : 124 - 130
  • [46] GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy
    Lin, Wey-Ran
    Chiang, Jy-Ming
    Liang, Kung-Hao
    Lim, Siew-Na
    Lai, Ming-Wei
    Tsou, Yung-Kuan
    Hsieh, Tzu-Yun
    Hsu, Chih-Kai
    Yeh, Chau-Ting
    MEDICINE, 2016, 95 (17)
  • [47] Adjuvant Chemotherapy With UFT/LV Versus UFT/LV Plus PSK in Stage II/III Colorectal Cancer
    Ogawa, Hiroomi
    Shiraishi, Takuya
    Okada, Takuhisa
    Miyamae, Yohei
    Motegi, Yoko
    Shirabe, Ken
    Saeki, Hiroshi
    ANTICANCER RESEARCH, 2024, 44 (02) : 805 - 814
  • [48] Adjuvant chemotherapy in patients with colorectal cancer. Is there a role in the older adult?
    Papamichael, Demetris
    Hernandez, Paul
    Mistry, Ronak
    Xenophontos, Eleni
    Kakani, Chandana
    EJSO, 2020, 46 (03): : 363 - 368
  • [49] Adjuvant therapy of stage II and III colon cancer
    de Gramont, A
    SEMINARS IN ONCOLOGY, 2005, 32 (06) : S11 - S14
  • [50] The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients
    Hsieh, Mei-Chin
    Thompson, Trevor
    Wu, Xiao-Cheng
    Styles, Timothy
    O'Flarity, Mary B.
    Morris, Cyllene R.
    Chen, Vivien W.
    CANCER MEDICINE, 2016, 5 (05): : 871 - 880